BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38741500)

  • 1. [AL Amyloidosis].
    Ueda M
    Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [AL amyloidosis, from diagnosis to treatment].
    Villesuzanne C; Jaccard A; Nicol M
    Rev Prat; 2020 Dec; 70(10):1137-1141. PubMed ID: 33739663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I Approach Light Chain Amyloidosis.
    Chowdhury RB; Leung N
    G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
    Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
    Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.
    Mauermann ML; Clarke JO; Litchy WJ; Obici L; Lousada I; Gertz MA;
    Adv Ther; 2023 Nov; 40(11):4695-4710. PubMed ID: 37658177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
    Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
    Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
    Zhang C; Huang X; Li J
    Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
    Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
    Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How we treat systemic light-chain amyloidosis.
    Chaulagain CP; Comenzo RL
    Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
    Wong SW; Fogaren T
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Light chain amyloidosis].
    Hegenbart U; Aus dem Siepen F; Schönland S
    Inn Med (Heidelb); 2023 Sep; 64(9):842-847. PubMed ID: 37540260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.